- Home
- CRIS vs CALC Comparison
CRIS vs CALC Comparison
Compare CRIS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | CALC |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 88.3M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRIS | CALC |
|---|---|---|
| Price | $0.76 | $0.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $16.67 | $10.00 |
| AVG Volume (30 Days) | 123.5K | ★ 459.7K |
| Earning Date | 03-19-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | $32.24 | N/A |
| Revenue Next Year | $66.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.75 | $0.46 |
| 52 Week High | $3.13 | $7.20 |
Technical Indicators
Market Signals| Indicator | CRIS | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 29.42 | 32.84 |
| Support Level | N/A | $0.49 |
| Resistance Level | $1.04 | $0.79 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 3.28 | 23.64 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.